Durvalumab (D) ± tremelimumab (T) plus chemotherapy (CT) in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y)

被引:2
作者
Cho, B. C. [1 ]
Luft, A. [2 ]
Alexander, J. A. Alatorre [3 ]
Geater, S. Lucien [4 ]
Laktionov, K. [5 ]
Sang-We, K. [6 ]
Ursol, G. [7 ]
Hussein, M. [8 ]
Farah, L. Lim [9 ]
Yang, C. T. [10 ]
Araujo, L. H. [11 ]
Saito, H. [12 ]
Reinmuth, N. [13 ]
Lai, Z. [14 ]
Mann, H. [15 ]
Shi, X. [16 ]
Peters, S. [17 ]
Garon, E. B. [18 ]
Mok, T. S. K. [19 ]
Johnson, M. L. [20 ]
机构
[1] Yonsei Canc Ctr, Div Med Oncol, Seoul, South Korea
[2] Leningrad Reg Clin Hosp, Dept Oncol Thorac Surg 1, St Petersburg, Russia
[3] Hlth Pharma Profess Res, Oncol, Mexico City, DF, Mexico
[4] Prince Songkla Univ, Ctr Canc, Hat Yai, Thailand
[5] Minist Hlth Russian Federat NN Blokhin NMRCO, Chemotherapeut Dept 17, Fed State Budgetary Inst NN Blokhin Natl Med Res, Moscow, Russia
[6] Univ Ulsan, Coll Med, Asan Med Ctr, Oncol, Seoul, South Korea
[7] Acinus, Med & Diagnost Ctr, Kropyvnytskyi, Ukraine
[8] Florida Canc Specialists Sarah Cannon Res Inst, Fac Hematol & Oncol, Leesburg, VA USA
[9] Queen Mary Univ London, Barts Thorax Ctr, London, England
[10] Chang Gung Mem Hosp, Med, Taoyuan, Taiwan
[11] Inst Nacl Canc INCA, Med Oncol, Rio De Janeiro, Brazil
[12] Kanagawa Canc Ctr, Thorac Oncol, Yokohama, Kanagawa, Japan
[13] Asklepios Lung Clin, Thorac Oncol, Munich, Germany
[14] AstraZeneca, Waltham, MA USA
[15] AstraZeneca, Cambridge, England
[16] AstraZeneca, Gaithersburg, MD USA
[17] Lausanne Univ, Med Oncol, Ctr Hosp Univ Vaudois, Lausanne, Switzerland
[18] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA USA
[19] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China
[20] Tennessee Oncol PLLC, Med Oncol, Sarah Cannon Res Inst, Nashville, TN USA
关键词
D O I
10.1016/j.annonc.2022.10.365
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
326P
引用
收藏
页码:S1569 / S1570
页数:2
相关论文
empty
未找到相关数据